Evidence map›Paper›PMID 25732245›Full record

ArticleCell stem cell2015

Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease.

Penelope J Hallett, Michela Deleidi, Arnar Astradsson, Gaynor A Smith, Oliver Cooper, Teresia M Osborn, Maria Sundberg, Michele A Moore, Eduardo Perez-Torres, Anna-Liisa Brownell and 3 more

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell stem cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06422208 (A Phase 1 Clinical Trial of Autologous iPSC-Derived Dopamine Neuron Transplantation for Parkinson's Disease), which is not on this map. Cited by 184 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
184citing papers in PubMed, 2 pooled it
19.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06422208 phase1enrolling by invitationnot on this mapstarted 2024, after this paper: background citation

A Phase 1 Clinical Trial of Autologous iPSC-Derived Dopamine Neuron Transplantation for Parkinson's Disease

TypeinterventionalSponsorPenelope J. Hallett, Ph.D.Ran2024 to 2027Enrolled6ConditionsParkinson DiseaseArmsAutologous midbrain dopamine neurons
3 · Its place in the literature

Who cites it

184 citing papers in PubMed, 2 syntheses or guidelines pooled it, 333 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Investigating the efficacy, methods, and challenges of induced pluripotent stem cells (iPSC) therapy in Parkinson's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Review
  7. Replicable generation and stable maintenance of rhesus macaque iPSCs forFrontiers in cell and developmental biology · 2026
    Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Current Development of iPSC-Based Modeling in Neurodegenerative Diseases.International journal of molecular sciences · 2025
    Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. The Programme for Manufacture of hPSC‑Based Products for AMD and PD.Advances in experimental medicine and biology · 2025
    Review
  18. Review
  19. Article
  20. Review

124 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Penelope J HallettNeuroregeneration Research Institute, McLean Hospital and Harvard Medical School, Belmont, MA 02478, USA.
Michela DeleidiNeuroregeneration Research Institute, McLean Hospital and Harvard Medical School, Belmont, MA 02478, USA.
Arnar AstradssonNeuroregeneration Research Institute, McLean Hospital and Harvard Medical School, Belmont, MA 02478, USA.
Gaynor A SmithNeuroregeneration Research Institute, McLean Hospital and Harvard Medical School, Belmont, MA 02478, USA.
Oliver CooperNeuroregeneration Research Institute, McLean Hospital and Harvard Medical School, Belmont, MA 02478, USA.
Teresia M OsbornNeuroregeneration Research Institute, McLean Hospital and Harvard Medical School, Belmont, MA 02478, USA.
Maria SundbergNeuroregeneration Research Institute, McLean Hospital and Harvard Medical School, Belmont, MA 02478, USA.
Michele A MooreNeuroregeneration Research Institute, McLean Hospital and Harvard Medical School, Belmont, MA 02478, USA; New England Primate Research Center, Harvard Medical School, Southborough, MA 01772, USA.
Eduardo Perez-TorresNeuroregeneration Research Institute, McLean Hospital and Harvard Medical School, Belmont, MA 02478, USA.
Anna-Liisa BrownellNeuroregeneration Research Institute, McLean Hospital and Harvard Medical School, Belmont, MA 02478, USA; MGH/HST Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.
James M SchumacherNeuroregeneration Research Institute, McLean Hospital and Harvard Medical School, Belmont, MA 02478, USA.
Roger D SpealmanNeuroregeneration Research Institute, McLean Hospital and Harvard Medical School, Belmont, MA 02478, USA; New England Primate Research Center, Harvard Medical School, Southborough, MA 01772, USA.
Ole IsacsonNeuroregeneration Research Institute, McLean Hospital and Harvard Medical School, Belmont, MA 02478, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA. Electronic address: isacson@hms.harvard.edu.
Harvard University · US

Funding

ZETA CHAIN OF T CELL RECEPTOR INTERACTS W/ NEF OF SIV &HIV2P51RR000168 · NCRR · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WESTMORELAND, SUSAN V. · 1985 to 2011
$139.3M
New England Primate Research Center Base GrantP51OD011103 · OD · HARVARD MEDICAL SCHOOL · PI FLIER, JEFFREY S · 2012 to 2013
$24.7M
Transplantation of ES Cell-derived DA Neurons into PD Primate ModelsP50NS039793 · NINDS · MC LEAN HOSPITAL (BELMONT, MA) · PI ISACSON, OLE · 1999 to 2010
$16.3M
MOUSE MODELS OF CANCER, BONE DISEASE, AND LACTATIONK26RR000168 · NCRR · OHIO STATE UNIVERSITY · PI ROSOL, THOMAS J · 2000 to 2004
$547k
NCRR NIH HHS K26 RR000168NCRR NIH HHS P51 RR000168NCRR NIH HHS RR00168NIH HHS P51 OD011103NINDS NIH HHS P50 NS039793NINDS NIH HHS P50 NS39793
6 · The paper itself

Abstract

Autologous transplantation of patient-specific induced pluripotent stem cell (iPSC)-derived neurons is a potential clinical approach for treatment of neurological disease. Preclinical demonstration of long-term efficacy, feasibility, and safety of iPSC-derived dopamine neurons in non-human primate models will be an important step in clinical development of cell therapy. Here, we analyzed cynomolgus monkey (CM) iPSC-derived midbrain dopamine neurons for up to 2 years following autologous transplantation in a Parkinson's disease (PD) model. In one animal, with the most successful protocol, we found that unilateral engraftment of CM-iPSCs could provide a gradual onset of functional motor improvement contralateral to the side of dopamine neuron transplantation, and increased motor activity, without a need for immunosuppression. Postmortem analyses demonstrated robust survival of midbrain-like dopaminergic neurons and extensive outgrowth into the transplanted putamen. Our proof of concept findings support further development of autologous iPSC-derived cell transplantation for treatment of PD.

Indexed as

Stem Cell TransplantationAnimalsAutograftsDisease Models, AnimalDopaminergic NeuronsHumansInduced Pluripotent Stem CellsMacaca fascicularisMesencephalonParkinson Disease

Identifiers

PMID25732245
PMCPMC4462124
OpenAlexW2083063722

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.